School of Medicine
Showing 1-8 of 8 Results
-
Stephen Chang, MD, PhD
Instructor, Biochemistry
Instructor, Medicine - Cardiovascular MedicineBioPrior to a career in medicine, Dr. Chang was an English major and subsequent novelist at night. During the days, he taught literature part-time at Rutgers University, and for extra money, worked in a laboratory in NYC washing test tubes. Inspired by his laboratory mentor, he began volunteering at the hospital next door, and developed a love for interacting with patients. Through this experience, he saw how caring for others could form deep bonds between people - even strangers - and connect us in a way that brings grandeur to ordinary life.
In addition to seeing patients, Dr. Chang is a physician-scientist devoted to advancing the field of cardiovascular medicine. His research has been focused on identifying a new genetic organism that better models human heart disease than the mouse. For this purpose, he has been studying the mouse lemur, the smallest non-human primate, performing cardiovascular phenotyping (vital signs, ECG, echocardiogram) on lemurs both in-bred (in France) and in the wild (in Madagascar) to try to identify mutant cardiac traits that may be heritable - and in the process, characterize the first high-throughput primate model of human cardiac disease. -
Paul Cheng MD PhD
Assistant Professor of Medicine (Cardiovascular Medicine)
BioDr. Cheng is a Cardiologist at Stanford University School of Medicine in the Department of Medicine and a member of the Cardiovascular Research Institute. Dr. Cheng received his BEng in Chemical Engineering and BSc in biology at MIT. He subsequently completed his MD/PhD at UCSF working in the Srivastava lab studying how extracellular morphogenic signals affect cardiac development and fate determination of cardiac progenitors. Dr. Cheng completed internal medicine residency and cardiology fellowship at Stanford. His current clinical focus is in amyloidosis and cardio-oncology. During his post doctoral research in the Quertermous lab, he pioneered the application of single cell transcriptomic and epigenetic techniques to study human vascular diseases including atherosclerosis and aneurysm, and applied these techniques to investigate molecular mechanisms behind genetic risk factors for several human vascular diseases including atherosclerosis, and aortopathies such as Marfan's and Loey-Dietz syndrome.
The Cheng lab takes a patient-to-bench-to-bedside approach to science. The lab focuses on elucidating new pathogenic mechanisms of human vascular diseases through combing human genetics and primary vascular disease tissues, with high-resolution transcriptomic and epigenetic profiling to generate novel hypothesis that are then tested in a variety of in vitro and in vivo models. The lab is focused on two broad questions: (1) understanding the biological underpinning of the differences in diseases propensities of different arterial segments in an individual (i.e. why do you have atherosclerosis and aneurysms in certain segments but not others), and (2) understanding the role of perivascular fibroblast in human vascular diseases.
Find out more about what the Cheng lab is up to, check out https://chenglab.stanford.edu -
Daniel Clark, MD, MPH
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
Clinical Assistant Professor, Pediatrics - CardiologyBioDr. Clark is a board-certified, fellowship-trained cardiologist with the Adult Congenital Heart Program at Stanford Health Care. He is also a clinical assistant professor with dual appointments in the Division of Cardiovascular Medicine, Department of Medicine and the Division of Cardiology, Department of Pediatrics at Stanford University School of Medicine.
Dr. Clark specializes in the diagnosis and treatment of adult congenital heart disease (ACHD) and the management of congenital and acquired heart disease in children. His clinical focus involves the combined use of cardiac magnetic resonance (CMR) and other imaging techniques to evaluate patients with known or suspected cardiovascular disease. Dr. Clarkâs extensive training and experience with these techniques include multiple fellowships in adult cardiology, cardiovascular imaging, and ACHD.
Dr. Clark is currently a co-investigator on multiple research studies. During his fellowship, he received a training grant from the National Institutes of Health enabling evaluation of the ability of CMR to diagnose COVID-19-associated heart inflammation among college athletes. He currently uses CMR to assess heart transplant outcomes in donors positive for hepatitis C virus. Dr. Clark also received a research grant from the Adult Congenital Heart Disease Association supporting a randomized, controlled clinical trial of cardiac rehabilitation among patients with Fontan failure.
Dr. Clark serves as a peer reviewer for multiple prestigious journals, including The New England Journal of Medicine, Circulation, Journal of the American College of Cardiology, and Journal of the American Heart Association (JAHA). He serves on the editorial board for both JAHA and Circulation: Cardiovascular Imaging. He is also a member of numerous professional medical societies, including the American College of Cardiology, the American Heart Association, and the Adult Congenital Heart Association. -
William Clusin, MD
Associate Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsCardiac action potentials; tissue culture, voltage, clamp technique; role of calcium in ischemia arrhythmias; coronary, artery disease; myocardial infarction.
-
John P. Cooke, MD, PhD
Professor of Medicine (Cardiovascular Medicine), Emeritus
Current Research and Scholarly InterestsOur translational research program in vascular regeneration is focused on generating and characterizing vascular cells from human induced pluripotential stem cells. We are also studying the therapeutic application of these cells in murine models of peripheral arterial disease. In these studies we leverage our longstanding interest in endothelial signaling, eg by nitric oxide synthase (NOS) as well as by nicotinic cholinergic receptors (nAChR).
